BIOMAT Database Logo BIOMAT Database Logo

Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia. 1992

C O Weingrill, and W Mussio, and C R Moraes, and E Portes, and R C Castro, and A M Lengyel
Department of Medicine, Escola Paulista de Medicina, Sao Paulo, Brazil.

OBJECTIVE To compare the effect of Parlodel SRO (Sandoz, Basel, Switzerland), a long-acting oral bromocriptine, to Parlodel (Sandoz) and to study the chronic effects of Parlodel SRO. METHODS The study was twofold: (1) random, double-blind and (2) open. METHODS Patients were studied in an academic environment. METHODS Hyperprolactinemic patients were selected. Sixteen patients were treated during 1 month. Ten patients completed the 1-year follow-up. METHODS Parlodel SRO or Parlodel was administered during 1 month (first 15 days: 5 mg/d; afterwards: 10 mg/d). Parlodel SRO was given during 1 year in variable doses (maximal 20 mg/d). METHODS Prolactin (PRL) levels, clinical improvement, and side effects were evaluated. RESULTS After 1 month, 63% of the patients in both groups had normal PRL and 43% had menses. Side effects were similar. After 1 year all patients except one had normal PRL levels, and 89% were ovulating. CONCLUSIONS The efficacy, tolerability, and long duration of action of Parlodel SRO make it an excellent alternative for the treatment of hyperprolactinemic patients.

UI MeSH Term Description Entries
D006966 Hyperprolactinemia Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8) Prolactin Hypersecretion Syndrome,Prolactin, Inappropriate Secretion,Hyperprolactinaemia,Inappropriate Prolactin Secretion,Inappropriate Prolactin Secretion Syndrome,Hyperprolactinemias,Hypersecretion Syndrome, Prolactin,Inappropriate Secretion Prolactin,Prolactin Secretion, Inappropriate,Secretion Prolactin, Inappropriate,Secretion, Inappropriate Prolactin,Syndrome, Prolactin Hypersecretion
D008297 Male Males
D008597 Menstrual Cycle The period from onset of one menstrual bleeding (MENSTRUATION) to the next in an ovulating woman or female primate. The menstrual cycle is regulated by endocrine interactions of the HYPOTHALAMUS; the PITUITARY GLAND; the ovaries; and the genital tract. The menstrual cycle is divided by OVULATION into two phases. Based on the endocrine status of the OVARY, there is a FOLLICULAR PHASE and a LUTEAL PHASE. Based on the response in the ENDOMETRIUM, the menstrual cycle is divided into a proliferative and a secretory phase. Endometrial Cycle,Ovarian Cycle,Cycle, Endometrial,Cycle, Menstrual,Cycle, Ovarian,Cycles, Endometrial,Cycles, Menstrual,Cycles, Ovarian,Endometrial Cycles,Menstrual Cycles,Ovarian Cycles
D008599 Menstruation Disturbances Variations of MENSTRUATION which may be indicative of disease. Hypomenorrhea,Menstruation Disorders,Menstruation, Retrograde,Polymenorrhea,Irregular Menses,Irregular Menstruation,Menstrual Irregularities,Menstrual Irregularity,Disorder, Menstruation,Disorders, Menstruation,Disturbance, Menstruation,Disturbances, Menstruation,Irregularity, Menstrual,Menses, Irregular,Menstruation Disorder,Menstruation Disturbance,Menstruation, Irregular,Retrograde Menstruation
D010060 Ovulation The discharge of an OVUM from a rupturing follicle in the OVARY. Ovulations
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

C O Weingrill, and W Mussio, and C R Moraes, and E Portes, and R C Castro, and A M Lengyel
New long-acting bromocriptine (Parlodel MR and Parlodel LAR) in the treatment of pituitary tumours with hyperprolactinemia.
January 1992, Endokrynologia Polska,
C O Weingrill, and W Mussio, and C R Moraes, and E Portes, and R C Castro, and A M Lengyel
[Parenteral, depot and repeatable forms of Parlodel LAR bromocriptine in the treatment of hyperprolactinemia syndrome. Comparison with oral Parlodel].
February 1993, Casopis lekaru ceskych,
C O Weingrill, and W Mussio, and C R Moraes, and E Portes, and R C Castro, and A M Lengyel
[Results of treatment for acromegaly with long-acting bromocriptine (Parlodel LAR)].
January 1993, Endokrynologia Polska,
C O Weingrill, and W Mussio, and C R Moraes, and E Portes, and R C Castro, and A M Lengyel
A new oral slow release form of bromocriptine, Parlodel SRO, in the chronic treatment of 26 hyperprolactinemic patients.
September 1991, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
C O Weingrill, and W Mussio, and C R Moraes, and E Portes, and R C Castro, and A M Lengyel
Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas.
May 1993, Fertility and sterility,
C O Weingrill, and W Mussio, and C R Moraes, and E Portes, and R C Castro, and A M Lengyel
Parlodel SRO in Parkinson's disease: a double-blind randomized comparison of Parlodel standard and Parlodel SRO.
January 1992, European neurology,
C O Weingrill, and W Mussio, and C R Moraes, and E Portes, and R C Castro, and A M Lengyel
Long-term treatment with a new repeatable injectable form of bromocriptine, Parlodel LAR, in patients with tumorous hyperprolactinemia.
December 1989, Fertility and sterility,
C O Weingrill, and W Mussio, and C R Moraes, and E Portes, and R C Castro, and A M Lengyel
Bromocriptine mesylate (Parlodel) in the management of amenorrhea/galactorrhea associated with hyperprolactinemia.
March 1980, Obstetrics and gynecology,
C O Weingrill, and W Mussio, and C R Moraes, and E Portes, and R C Castro, and A M Lengyel
[Long-term treatment of acromegaly with bromocriptine (Parlodel R)].
September 1977, Vnitrni lekarstvi,
C O Weingrill, and W Mussio, and C R Moraes, and E Portes, and R C Castro, and A M Lengyel
Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients.
January 1996, Journal of endocrinological investigation,
Copied contents to your clipboard!